We have 3 of 34 papers
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
Patients with type 2 diabetes face a high residual risk of atherosclerotic cardiovascular disease (ASCVD) despite advances in therapy. Once-weekly IcoSema, a fixed-ratio combination of basal insulin icodec and semaglutide, offers the potential to simultaneously address glycemic control, weight, and multiple cardiometab...
SGLT-2 inhibitors provide a modest incremental benefit in lowering office systolic blood pressure for patients with uncontrolled or resistant hypertension on multidrug regimens with an overall acceptable safety profile.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
